top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma approvals, new data, M&A activity, and more - March 29th 2024

Oral dual GLP-1/GIP obesity data + 14 more major updates...👇

🎯 → Approvals

🔬 → New data

🤝 → M&A activity


🎯 FDA approved WINREVAIR™ (sotatercept-csrk) treating adults with pulmonary arterial hypertension.

🎯 EC approved KEYTRUDA® (pembrolizumab) + chemotherapy as neoadjuvant Treatment, then continued as monotherapy as adjuvant treatment NSCLC.


🎯 Received FDA approval for Vafseo® (vadadustat) for the treatment of anemia due to CKD in adult patients on dialysis. 

Endo International 

🎯 Received approval in Canada for WAKIX® (pitolisant hydrochloride tablets) for use in pediatric patients.

Amneal Pharmaceuticals, Inc.

🎯 FDA Approved Ciprofloxacin and Dexamethasone otic suspension for the treatment of infections. 

Esperion Therapeutics

🎯 Received FDA approved for broad new labels for NEXLETOL® and NEXLIZET® to prevent heart attacks and cardiovascular procedures. 


🎯 FDA approved Ultomiris treating NMOSD.  

🎯 Beyfortus received approval in Japan for the prevention of RSV disease in infants, and Truqap + Faslodex treating advanced HR-positive breast cancer.

Zevra Therapeutics 

🔬 Topline data reported from the Ph2 trial of KP1077 for idiopathic hypersomnia.

Viking Therapeutics

🔬 Reported results from the Ph1 trial of oral tablet formulation of dual GLP-1/GIP receptor agonist VK2735.

Inozyme Pharma 

🔬 Report topline data on Apr. 8, 2024 for the Ph1/2 trials of INZ-701. 

Sellas Life Sciences 

🔬 Topline data reported from the Ph2a trial of SLS009 in r/r AML. 


Ceapro & Aeterna Zentaris

🤝 Received final court approval for merger with Aeterna Zentaris.

Avalo Therapeutics & AlmataBio

🤝 Announced the acquisition of AlmataBio.


Interested in these updates? Get the full update each week → 


March 25-29, 2024

Article History:

RF, DV (03/29/24)


bottom of page